According to Alexandria Real Estate Equities 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 89.2518. At the end of 2022 the company had a P/E ratio of 46.5.
Year | P/E ratio | Change |
---|---|---|
2022 | 46.5 | -20.89% |
2021 | 58.8 | 93.43% |
2020 | 30.4 | -41.65% |
2019 | 52.1 | 60.57% |
2018 | 32.5 | -60.72% |
2017 | 82.7 | -248.75% |
2016 | -55.6 | -200.85% |
2015 | 55.1 | -37.29% |
2014 | 87.9 | 120.97% |
2013 | 39.8 | -37.48% |
2012 | 63.6 | 58.6% |
2011 | 40.1 | 18.77% |
2010 | 33.8 | 45.46% |
2009 | 23.2 | 10.39% |
2008 | 21.0 | -45.2% |
2007 | 38.4 | -12.87% |
2006 | 44.0 | 23.63% |
2005 | 35.6 | 19.22% |
2004 | 29.9 | 67.71% |
2003 | 17.8 | -25.14% |
2002 | 23.8 | -3.3% |
2001 | 24.6 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Pfizer PFE | 15.5 | -82.58% | ๐บ๐ธ USA |
Eli Lilly LLY | 142 | 59.13% | ๐บ๐ธ USA |
Amgen AMGN | 22.2 | -75.08% | ๐บ๐ธ USA |
Gilead Sciences GILD | 15.5 | -82.68% | ๐บ๐ธ USA |
Illumina ILMN | -4.30 | -104.82% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | 11.1 | -87.55% | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | -36.8 | -141.22% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.